Soon after Fiona Marshall took over the leadership of Novartis Biomedical Research in November 2022, she accelerated the collaboration between the research, development, and commercial organizations of Novartis. In her view, this move is not a renunciation of the company’s basic scientific efforts, but an attempt to create research platforms with high productivity to develop breakthrough medicines for patients around the world.
By Goran Mijuk
Published on 11/09/2024
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.